相关实验视频
Updated: Jun 30, 2025

05:25
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
708
在冠状动脉旁路移植中预防移植失败的抗血栓策略
Maria Sara Mauro1, Simone Finocchiaro1, Dario Calderone1
1Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico "G. Rodolico-San Marco", University of Catania, Via Santa Sofia, 78, Catania, Italy.
Journal of thrombosis and thrombolysis
|March 16, 2024
概括
在冠状动脉旁路移植 (CABG) 后最佳的抗血栓策略尚不清楚. 这份随机试验的综述评估了抗血小板和抗凝疗法,以改善移植的通透性并减少不良事件.
科学领域:
- 心血管外科心血管外科
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 冠状动脉旁路移植 (CABG) 被由于血栓形成,增生和动脉样硬化而导致的移植失败所挑战.
- 在CABG后最佳的抗血栓治疗是不确定的,缺乏明确的指导方针,并依赖于专家意见.
- 移植闭塞显著影响CABG后患者的长期结果.
研究的目的:
- 审查CABG患者抗血栓治疗的随机临床试验和元分析.
- 评估各种抗血栓治疗方案的有效性和安全性,以预防移植失败.
- 在CABG后,为有关抗血栓策略的临床决策提供信息.
主要方法:
- 随机临床试验和元分析的系统审查.
- 对抗血小板策略的分析,包括单抗血小板治疗 (阿司匹林,P2Y12抑制剂),双抗血小板治疗和抗凝药.
- 评估移植的通透性,主要的不良心血管事件和出血并发症.
主要成果:
- 阿司匹林已成为CABG后抗血栓治疗的基石.
- 将P2Y12抑制剂添加到阿司匹林在随机对照试验中显示出混合的结果.
- 预防移植塞和最大限度地减少出血风险之间的最佳平衡需要进一步调查.
结论:
- 目前关于CABG后最佳抗血栓策略的证据是不确定的.
- 需要进一步的研究,以建立CABG后抗血栓治疗的最终指导方针.
- 个性化抗血栓治疗方法可能是必要的,以优化长期CABG结果.
更多相关视频
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428

